Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22332139 | 1.00 | CHRM1 (0.50) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL22332137 | 1.00 | CHRM1 (0.50) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL20273204 | 1.00 | CHRM1 (0.50) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL22837943 | 1.00 | CHRM1 (0.50) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL22332138 | 1.00 | CHRM1 (0.50) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL22837941 | 1.00 | CHRM1 (0.50) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL17061265 | 0.93 | CHRM1 (0.52) | CHRM1CHRM2CHRM3PREPMEN1 | |
| SCHEMBL30994513 | 0.84 | CHRM2 (0.54) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL15239715 | 0.84 | CHRM2 (0.54) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL413955 | 0.84 | CHRM2 (0.54) | CHRM1CHRM2CHRM3PREPHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912775-B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10912775-B2 | Crystal form of orexin receptor antagonist compound, and preparation method and application thereof | HCRTR2, HCRTR1, NPY5R | CHRM1 282/4885CHRM2 275/4885CHRM3 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.